About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company headquartered in Boston, Massachusetts, the world leader in cystic fibrosis medicines and expanding into gene editing and pain.
Milestones
Milestones as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Charles F. Wagner, Jr.
Carmen Bozic, M.D.
Products & Services
Products and services as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor)
Once-daily triple-combination CFTR modulator; Vertex expects most CF patients to transition to it over time.
Source: sec.govTRIKAFTA / KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Triple-combination CFTR modulator treating the underlying cause of cystic fibrosis.
Source: sec.govSYMDEKO / SYMKEVI (tezacaftor/ivacaftor and ivacaftor)
Combination CFTR modulator for cystic fibrosis.
Source: sec.govORKAMBI (lumacaftor/ivacaftor)
Combination CFTR modulator for cystic fibrosis.
Source: sec.govCASGEVY (exagamglogene autotemcel)
Ex-vivo CRISPR/Cas9 gene-edited cell therapy for severe SCD and transfusion-dependent beta thalassemia.
Source: sec.govJOURNAVX (suzetrigine)
First-in-class oral NaV1.8 pain signal inhibitor for moderate-to-severe acute pain in adults, a non-opioid option.
Source: sec.govPipeline & Regulatory Record
What public registers list for Vertex Pharmaceuticals: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 7 Oct 2026.
Clinical trials 30 in our ClinicalTrials.gov registers · 2 in the EU register
Showing 10 of 30, trials with Irish sites first. The full lists are on the sponsor pages below.
All trials by sponsor name 1 registry name
Drugs in these trials 18 compounds
EU trials register (CTIS) 2 authorised or ongoing · 1 in Ireland
- A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis2025-523400-72-00 · Phase II · Authorised · site in Ireland
- A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants2024-517393-13-00 · Phase II · Ongoing
NICE technology appraisals 4 of its medicines · 4 current
- Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and overNICE TA1085 · Optimised · 30 Jul 2025
- Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and overNICE TA1044 · Optimised (Innovative Medicines Fund) · 26 Feb 2025
- Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and overNICE TA1003 · Recommended (Innovative Medicines Fund) · 11 Sep 2024
- Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosisNICE TA988 · Recommended · 24 Jul 2024
Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Group (Vertex Pharmaceuticals): founded 1989, headquarters Boston, website vrtx.com. Wikidata Q2744099 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.
How this is matched: register records are linked to this page by the organisation name they carry, here Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Inc.; Vertex Pharmaceuticals (Ireland) Limited; VERTEX PHARMS. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports Vertex Pharmaceuticals Incorporated files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $12.00bn | $3.91bn | 32.6% | $3.95bn | 10-K 2026 |
| Dec 2024 | $11.02bn | $3.63bn | 32.9% | −$536m | 10-K 2026 |
| Dec 2023 | $9.87bn | $3.16bn | 32.0% | $3.62bn | 10-K 2026 |
| Dec 2022 | $8.93bn | $2.54bn | 28.4% | $3.32bn | 10-K 2025 |
| Dec 2021 | $7.57bn | $3.05bn | 40.3% | $2.34bn | 10-K 2024 |
R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.
Companies registered in Ireland 4 active in the CRO register
| Company | CRO no. | Registered | Last accounts |
|---|---|---|---|
| Vertex Pharmaceuticals (Ireland) Limited LTD - Private Company Limited by Shares | 502558 | 2011 | Dec 2025 |
| Vertex Pharmaceuticals (Europe) Limited External company | 909808 | 2022 | — |
| Vertex Pharmaceuticals Finance Unlimited Company ULC - Private Unlimited Company | 814313 | 2026 | — |
| Vertex Pharmaceuticals Ireland Holding Unlimited Company ULC - Private Unlimited Company | 814314 | 2026 | — |
From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Vertex Pharmaceuticals Incorporated as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.